tirzepatide category Shifts in body mass index

Retatrutide is an investigational injectable triple agonist targeting GLP-1, GIP, and glucagon receptors, currently in clinical trials for obesity and type 2 diabetes but not yet approved by the MHRA or EMA

A GLP-1R agonist/GIPR antagonist peptide is theoretically possible but few full-length GIP-like antagonists were reported, 60 therefore it requires an array of attempts, at least an alanine-scan experiment of GIP with measuring of affinity

PlexusDx providers can help coordinate this transition and discuss when resuming compounded semaglutide might be appropriate after pregnancy and breastfeeding (typically 6-12 months postpartum, depending on individual factors)

Lanluma Bum Filler: For a more targeted approach, Dr